Abstract
Summary
The global Toxic Epidermal Neurolysis market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Toxic Epidermal Neurolysis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Toxic Epidermal Neurolysis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Toxic Epidermal Neurolysis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Toxic Epidermal Neurolysis players cover Pfizer, Novartis, Sanofi, Merck and Co, Sun pharma, Abbott laboratories, Johnson & Johnson, Teva pharmaceuticals and Viatris, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Toxic epidermal neurolysis, or TEN syndromes, are rare, severe forms of Stevens-Johnson syndrome (SJS). SJS only causes skin to blister and peel on roughly 10% of the body. When between 10% and 30% of the body is covered, both situations exist. Every year, SJS, as well as TEN, together impact between 1 and 2 million people.
LPI (LP Information)' newest research report, the “Toxic Epidermal Neurolysis Industry Forecast” looks at past sales and reviews total world Toxic Epidermal Neurolysis sales in 2022, providing a comprehensive analysis by region and market sector of projected Toxic Epidermal Neurolysis sales for 2023 through 2029. With Toxic Epidermal Neurolysis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Toxic Epidermal Neurolysis industry.
This Insight Report provides a comprehensive analysis of the global Toxic Epidermal Neurolysis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Toxic Epidermal Neurolysis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Toxic Epidermal Neurolysis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Toxic Epidermal Neurolysis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Toxic Epidermal Neurolysis.
This report presents a comprehensive overview, market shares, and growth opportunities of Toxic Epidermal Neurolysis market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibiotics
Corticosteroids
Intravenous Immunoglobulins
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Sanofi
Merck and Co
Sun pharma
Abbott laboratories
Johnson & Johnson
Teva pharmaceuticals
Viatris
United States market for Toxic Epidermal Neurolysis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Toxic Epidermal Neurolysis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Toxic Epidermal Neurolysis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Toxic Epidermal Neurolysis players cover Pfizer, Novartis, Sanofi, Merck and Co, Sun pharma, Abbott laboratories, Johnson & Johnson, Teva pharmaceuticals and Viatris, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Toxic epidermal neurolysis, or TEN syndromes, are rare, severe forms of Stevens-Johnson syndrome (SJS). SJS only causes skin to blister and peel on roughly 10% of the body. When between 10% and 30% of the body is covered, both situations exist. Every year, SJS, as well as TEN, together impact between 1 and 2 million people.
LPI (LP Information)' newest research report, the “Toxic Epidermal Neurolysis Industry Forecast” looks at past sales and reviews total world Toxic Epidermal Neurolysis sales in 2022, providing a comprehensive analysis by region and market sector of projected Toxic Epidermal Neurolysis sales for 2023 through 2029. With Toxic Epidermal Neurolysis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Toxic Epidermal Neurolysis industry.
This Insight Report provides a comprehensive analysis of the global Toxic Epidermal Neurolysis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Toxic Epidermal Neurolysis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Toxic Epidermal Neurolysis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Toxic Epidermal Neurolysis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Toxic Epidermal Neurolysis.
This report presents a comprehensive overview, market shares, and growth opportunities of Toxic Epidermal Neurolysis market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibiotics
Corticosteroids
Intravenous Immunoglobulins
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Sanofi
Merck and Co
Sun pharma
Abbott laboratories
Johnson & Johnson
Teva pharmaceuticals
Viatris
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Toxic Epidermal Neurolysis Market Size 2018-2029
2.1.2 Toxic Epidermal Neurolysis Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Toxic Epidermal Neurolysis Segment by Type
2.2.1 Antibiotics
2.2.2 Corticosteroids
2.2.3 Intravenous Immunoglobulins
2.3 Toxic Epidermal Neurolysis Market Size by Type
2.3.1 Toxic Epidermal Neurolysis Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Toxic Epidermal Neurolysis Market Size Market Share by Type (2018-2023)
2.4 Toxic Epidermal Neurolysis Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Toxic Epidermal Neurolysis Market Size by Application
2.5.1 Toxic Epidermal Neurolysis Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Toxic Epidermal Neurolysis Market Size Market Share by Application (2018-2023)
3 Toxic Epidermal Neurolysis Market Size by Player
3.1 Toxic Epidermal Neurolysis Market Size Market Share by Players
3.1.1 Global Toxic Epidermal Neurolysis Revenue by Players (2018-2023)
3.1.2 Global Toxic Epidermal Neurolysis Revenue Market Share by Players (2018-2023)
3.2 Global Toxic Epidermal Neurolysis Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Toxic Epidermal Neurolysis by Regions
4.1 Toxic Epidermal Neurolysis Market Size by Regions (2018-2023)
4.2 Americas Toxic Epidermal Neurolysis Market Size Growth (2018-2023)
4.3 APAC Toxic Epidermal Neurolysis Market Size Growth (2018-2023)
4.4 Europe Toxic Epidermal Neurolysis Market Size Growth (2018-2023)
4.5 Middle East & Africa Toxic Epidermal Neurolysis Market Size Growth (2018-2023)
5 Americas
5.1 Americas Toxic Epidermal Neurolysis Market Size by Country (2018-2023)
5.2 Americas Toxic Epidermal Neurolysis Market Size by Type (2018-2023)
5.3 Americas Toxic Epidermal Neurolysis Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Toxic Epidermal Neurolysis Market Size by Region (2018-2023)
6.2 APAC Toxic Epidermal Neurolysis Market Size by Type (2018-2023)
6.3 APAC Toxic Epidermal Neurolysis Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Toxic Epidermal Neurolysis by Country (2018-2023)
7.2 Europe Toxic Epidermal Neurolysis Market Size by Type (2018-2023)
7.3 Europe Toxic Epidermal Neurolysis Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Toxic Epidermal Neurolysis by Region (2018-2023)
8.2 Middle East & Africa Toxic Epidermal Neurolysis Market Size by Type (2018-2023)
8.3 Middle East & Africa Toxic Epidermal Neurolysis Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Toxic Epidermal Neurolysis Market Forecast
10.1 Global Toxic Epidermal Neurolysis Forecast by Regions (2024-2029)
10.1.1 Global Toxic Epidermal Neurolysis Forecast by Regions (2024-2029)
10.1.2 Americas Toxic Epidermal Neurolysis Forecast
10.1.3 APAC Toxic Epidermal Neurolysis Forecast
10.1.4 Europe Toxic Epidermal Neurolysis Forecast
10.1.5 Middle East & Africa Toxic Epidermal Neurolysis Forecast
10.2 Americas Toxic Epidermal Neurolysis Forecast by Country (2024-2029)
10.2.1 United States Toxic Epidermal Neurolysis Market Forecast
10.2.2 Canada Toxic Epidermal Neurolysis Market Forecast
10.2.3 Mexico Toxic Epidermal Neurolysis Market Forecast
10.2.4 Brazil Toxic Epidermal Neurolysis Market Forecast
10.3 APAC Toxic Epidermal Neurolysis Forecast by Region (2024-2029)
10.3.1 China Toxic Epidermal Neurolysis Market Forecast
10.3.2 Japan Toxic Epidermal Neurolysis Market Forecast
10.3.3 Korea Toxic Epidermal Neurolysis Market Forecast
10.3.4 Southeast Asia Toxic Epidermal Neurolysis Market Forecast
10.3.5 India Toxic Epidermal Neurolysis Market Forecast
10.3.6 Australia Toxic Epidermal Neurolysis Market Forecast
10.4 Europe Toxic Epidermal Neurolysis Forecast by Country (2024-2029)
10.4.1 Germany Toxic Epidermal Neurolysis Market Forecast
10.4.2 France Toxic Epidermal Neurolysis Market Forecast
10.4.3 UK Toxic Epidermal Neurolysis Market Forecast
10.4.4 Italy Toxic Epidermal Neurolysis Market Forecast
10.4.5 Russia Toxic Epidermal Neurolysis Market Forecast
10.5 Middle East & Africa Toxic Epidermal Neurolysis Forecast by Region (2024-2029)
10.5.1 Egypt Toxic Epidermal Neurolysis Market Forecast
10.5.2 South Africa Toxic Epidermal Neurolysis Market Forecast
10.5.3 Israel Toxic Epidermal Neurolysis Market Forecast
10.5.4 Turkey Toxic Epidermal Neurolysis Market Forecast
10.5.5 GCC Countries Toxic Epidermal Neurolysis Market Forecast
10.6 Global Toxic Epidermal Neurolysis Forecast by Type (2024-2029)
10.7 Global Toxic Epidermal Neurolysis Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Toxic Epidermal Neurolysis Product Offered
11.1.3 Pfizer Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Toxic Epidermal Neurolysis Product Offered
11.2.3 Novartis Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Toxic Epidermal Neurolysis Product Offered
11.3.3 Sanofi Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 Merck and Co
11.4.1 Merck and Co Company Information
11.4.2 Merck and Co Toxic Epidermal Neurolysis Product Offered
11.4.3 Merck and Co Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Merck and Co Main Business Overview
11.4.5 Merck and Co Latest Developments
11.5 Sun pharma
11.5.1 Sun pharma Company Information
11.5.2 Sun pharma Toxic Epidermal Neurolysis Product Offered
11.5.3 Sun pharma Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sun pharma Main Business Overview
11.5.5 Sun pharma Latest Developments
11.6 Abbott laboratories
11.6.1 Abbott laboratories Company Information
11.6.2 Abbott laboratories Toxic Epidermal Neurolysis Product Offered
11.6.3 Abbott laboratories Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Abbott laboratories Main Business Overview
11.6.5 Abbott laboratories Latest Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Toxic Epidermal Neurolysis Product Offered
11.7.3 Johnson & Johnson Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Johnson & Johnson Main Business Overview
11.7.5 Johnson & Johnson Latest Developments
11.8 Teva pharmaceuticals
11.8.1 Teva pharmaceuticals Company Information
11.8.2 Teva pharmaceuticals Toxic Epidermal Neurolysis Product Offered
11.8.3 Teva pharmaceuticals Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Teva pharmaceuticals Main Business Overview
11.8.5 Teva pharmaceuticals Latest Developments
11.9 Viatris
11.9.1 Viatris Company Information
11.9.2 Viatris Toxic Epidermal Neurolysis Product Offered
11.9.3 Viatris Toxic Epidermal Neurolysis Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Viatris Main Business Overview
11.9.5 Viatris Latest Developments
12 Research Findings and Conclusion